NCT01428596View on ClinicalTrials.gov

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIVAX

Vaccine 1.0 ml SQ lower dose (10\^8 TU) at weeks 0, 8 and 16.

BIOLOGICAL

saline solution

Saline solution 1.0 ml SQ at weeks 0, 8 and 16.

BIOLOGICAL

HIVAX

Vaccine 1.0 ml SQ higher dose (10\^9 TU) at weeks 0, 8 and 16.

Trial Locations (1)

33136

University of Miami School of Medicine, AIDS Clinical Research unit, Miami

Sponsors
All Listed Sponsors
lead

GeneCure Biotechnologies

INDUSTRY